Non-invasive prenatal detection of achondroplasia using circulating fetal DNA in maternal plasma

J Assist Reprod Genet. 2011 Feb;28(2):167-72. doi: 10.1007/s10815-010-9489-1. Epub 2010 Oct 21.

Abstract

Purpose: To perform a reliable non-invasive detection of the fetal achondroplasia using maternal plasma.

Methods: We developed a quantitative fluorescent-polymerase chain reaction (QF-PCR) method suitable for detection of the FGFR3 mutation (G1138A) causing achondroplasia. This method was applied in a non-invasive detection of the fetal achondroplasia using circulating fetal-DNA (cf-DNA) in maternal plasma. Maternal plasmas were obtained at 27 weeks of gestational age from women carrying an achondroplasia fetus or a normal fetus.

Results: Two percent or less achondroplasia DNA was reliably detected by QF-PCR. In a woman carrying a normal fetus, analysis of cf-DNA showed only one peak of the wild-type G allele. In a woman expected an achondroplasia fetus, analysis of cf-DNA showed the two peaks of wild-type G allele and mutant-type A allele and accurately detected the fetal achondroplasia.

Conclusions: The non-invasive method using maternal plasma and QF-PCR may be useful for diagnosis of the fetal achondroplasia.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Achondroplasia / blood*
  • Achondroplasia / diagnosis*
  • Achondroplasia / genetics
  • DNA / blood*
  • Female
  • Genotype
  • Humans
  • Maternal-Fetal Exchange
  • Point Mutation / genetics
  • Polymerase Chain Reaction / methods*
  • Pregnancy
  • Prenatal Diagnosis / methods*
  • Receptor, Fibroblast Growth Factor, Type 3 / blood
  • Receptor, Fibroblast Growth Factor, Type 3 / genetics*

Substances

  • DNA
  • Receptor, Fibroblast Growth Factor, Type 3